News Column

Recent Studies from Vall Hebron University Hospital Add New Data to Cancer Gene Therapy

June 23, 2014



By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- New research on Biotechnology is the subject of a report. According to news reporting out of Barcelona, Spain, by NewsRx editors, research stated, "Non-small-cell lung cancer (NSCLC) represents approximately 85% of all lung cancer cases, with a worldwide annual incidence of around 1.3 million. Surgery remains the corner stone of treatment in early-stage NSCLC when feasible, and the addition of adjuvant cisplatin-based chemotherapy has improved these results in resected NSCLC patients."

Our news journalists obtained a quote from the research from Vall Hebron University Hospital, "For those patients with non-metastatic NSCLC not suitable for complete surgical resection, chemotherapy plus radiotherapy remains the best treatment option. For patients with metastatic NSCLC, molecular targeted agents have become part of the therapeutic arsenal in recent years. However, to date no targeted agent has been approved for patients with early or locally-advanced stages of NSCLC."

According to the news editors, the research concluded: "Here, we review the rationale, literature and studies addressing the role of targeted agents used in the adjuvant setting or as part of chemoradiotherapy regimens."

For more information on this research see: Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate? Lung Cancer, 2014;84(2):97-100. Lung Cancer can be contacted at: Elsevier Ireland Ltd, Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland. (Elsevier - www.elsevier.com; Lung Cancer - www.elsevier.com/wps/product/cws_home/505953)

Our news journalists report that additional information may be obtained by contacting P. Martinez, Vall Hebron Univ Hosp, Dept. of Med Oncol, Barcelona, Spain. Additional authors for this research include A. Martinez-Marti, A. Navarro, S. Cedres and E. Felip (see also Biotechnology).

Keywords for this news article include: Biotechnology, Spain, Europe, Oncology, Barcelona, Lung Neoplasms, Cancer Gene Therapy, Non-Small Cell Lung Cancer

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters